Twitter Logo Youtube Circle Icon LinkedIn Icon

United States > Industry focus > Healthcare: life sciences > Law firm and leading lawyer rankings


Index of tables

  1. Healthcare: life sciences
  2. Leading lawyers
  3. Next generation lawyers

Next generation lawyers

  1. 1

Who Represents Who

Find out which law firms are representing which Healthcare: life sciences clients in United States using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact


The ‘top-drawer’ life sciences practice at Covington & Burling LLP is singled out for its ‘fantastic technical ability’, its ‘deep industry knowledge’, and its capacity to ‘draw resources from across its organization and present it as a single team’. It has an exceptional regulatory and corporate practice, regularly acting for major global pharmaceutical and biotechnology companies on a range of commercial agreements supporting a product life cycle. The group’s regulatory capability was enhanced by the arrival of Los Angeles-based Wade Ackerman, who joined from the US Senate Health, Education, Labor & Pensions (HELP) Committee. The team represented a major pharmaceutical company in an investigation by the House Oversight and Government Reform Committee regarding alleged off-label marketing of pharmaceutical products. On the transactional front, John Hurvitz advised AbbVie on its global collaboration with Boehringer Ingelheim for an anti-IL-23 monoclonal biological antibody and, in another deal, assisted AbbVie with its $5.8bn acquisition of Stemcentrx and its rovalpituzumab compound for small cell lung cancer. Silicon Valley-based Emily Leonard counts Astellas, Foundation Medicine and Gilead among her clients; she recently assisted Medarex in collaborating with a Japanese pharmaceutical company over the cross-licensing of platform technologies. Senior counsels Richard Kingham, Peter Safir, Peter Barton Hutt, and partners Denise Esposito and Ellen Flannery are the key names to note in the regulatory and compliance space. Patent litigator Jeffrey Lerner and Hatch-Waxman litigation specialist George Pappas are also highly recommended. Named individuals are based in Washington DC unless otherwise stated.

In the words of one client, Sidley Austin LLP’s team is ‘extremely valuable’, ‘articulate and very insightful in its legal advice’. Led by Raymond Bonner and Coleen Klasmeier, the group has a widely recognized regulatory and compliance practice, which assists clients in more than 20 countries and across a number of industries on current good manufacturing practice, quality system regulation and good clinical practice issues; the practice further strengthened its regulatory capability with the recent addition of Nancy Stade from the Food and Drug Administration (FDA). The ‘extremely knowledgeable’ Paul Kalb and Jaime Jones have been representing Novo Nordisk in a joint criminal and civil investigation conducted by the Department of Justice and the US Attorney’s Office for the District of Columbia into alleged improper promotion of one of the company’s products. Chicago-based David Pritkin is representing Johnson & Johnson in a Hatch-Waxman litigation against 12 generic drug manufacturers which is pending in the US District Court for the District of New Jersey, and has parallel proceedings in Europe and Australia. Scott Bass heads the global life sciences team, in which Sam Zucker is ‘a very savvy biotech corporate attorney’; Richard Raskin focuses on healthcare litigation involving antitrust, fraud and abuse and reimbursement issues; New York-based IP litigators Jim Badke and Sona De, the latter having joined from Ropes & Gray LLP, are also key contacts.

Arnold & Porter’s reputation rests on its outstanding product liability defense, IP litigation and regulatory capabilities. The combination of Arnold & Porter LLP and Kaye Scholer LLP resulted in a greater life sciences platform, allowing the practice to advise clients on a broad range of high-profile and often cross-border matters. The team - which notably includes drug pricing and investigation specialists Jeffrey Handwerker, Ariane Horn and Mahnu Davar - counts the Pharmaceutical Manufacturers Association (phRMA) as a client; it recently filed a high-profile False Claims Act case alleging that CCS Medical took kickbacks disguised as discounts in exchange for converting patients to use of products sold by Coloplast. The practice also acted for The Halifax Group and its portfolio company NPC Guardian Holdings in the sale of its interest in Nutrition Physiology and Guardian Food Technologies to The Chr. Hansen, and advised Idera Pharmaceuticals on the negotiation of a license and collaboration agreement with GlaxoSmithKline regarding the modulation of gene targets. On the IP side, David Marsh has been assisting Monsanto with patent prosecution and multi-party opposition proceedings. Matthew Wolf is representing HyClone Laboratories, a subsidiary of General Electric, in patent infringement litigation brought by Janssen Biotech concerning a biosimilar for Remicade (infliximab) that is manufactured using custom cell culture media supplied by HyClone. Building on the firm’s track record of success at early stages in product liability cases concerning the antipsychotic treatment Abilify, New York-based product liability specialist Anand Agneshwar has been acting for Bristol-Myers Squibb in a number of proceedings concerning Plavix and other prescription drugs. Trial and appellate lawyer William Hoffman also often represents clients in product liability cases and other complex litigation. Daniel Kracov and Allison Shuren co-chair the FDA/healthcare practice group from the firm’s Washington DC office, where all individuals mentioned above are based unless otherwise stated.

Hogan Lovells US LLP’s reputation rests on its outstanding regulatory and transactional capabilities and its deep involvement in the digital health space assisting a number of global pharmaceutical companies in high-profile transactions. The seasoned practice group includes ‘a number of subject matter experts who weave their legal expertise with business know-how that results in well-rounded service’. According to one client, Adam Golden is ‘the single best life science transaction attorney’ - his recent work includes assisting Allergan with its $40.5bn divestment of its generics division to Teva and, with the support from highly recommended counsel Anishiya Abrol, advising Novartis on its $2.6bn partnership with Xencor to develop bispecific antibodies intended to fight acute cancers. Asher Rubin, who is global head of the life sciences and healthcare industry team, acts for private and publicly traded businesses, venture capital and private equity funds in a wide range of transactions. Washington DC-based David Fox and Philip Katz are ‘twin-tower regulatory powers’. Philadelphia-based Janice Hogan and Susan Lee are FDA specialists - recent mandates for the FDA litigation team include challenging the Drug Enforcement Agency (DEA) to withdraw its notice of intent to use DEA’s emergency scheduling authority to place the active components of the botanical product, Kratom, under Schedule I of the Controlled Substances Act. Other recent highlights include representing Bristol-Myers Squibb in a multi-jurisdictional product liability litigation and acting for DepoMed in a patent infringement case against Endo Pharmaceuticals relating to Endo’s pain management drug, Opana ER. The team bolstered its IP litigation capability with the arrival of New York-based Michael Dougherty and Tony Pezzano, who joined from King & Spalding LLP. Laura Berezin moved to Cooley LLP.

Latham & Watkins LLP’s corporate group, which clients praise for its ‘excellent service’, is very active in the life sciences industry. Silicon Valley-based Alan Mendelson, Mark Roeder and Josh Dubofsky assisted Kythera Biopharmaceuticals with its $2.1bn sale to Allergan, while Orange County-based Charles Ruck and R Scott Shean acted for Allergan on the $40.5bn sale of its global generic pharmaceuticals business to Teva. The capital markets team routinely assists issuers and underwriters including Novan, Medpace Holdings and JP Morgan Securities with the IPOs of shares of common stock listed on Nasdaq or other platforms. On the regulatory front, Washington DC-based John Manthei assists clients with all aspects of the lifecycle of FDA-regulated products, such as advising Boston Scientific and the Medical Device Manufacturers Association (MDMA) on the medical device industry’s negotiations with the FDA, the White House and US Congress over the 21st Century Care Initiative. The intellectual property litigation team includes a number of well-regarded attorneys such as Michael Morin, David Frazier and Casey Dwyer in Washington DC and New York-based Daniel Brown. The team successfully represented AbbVie in two inter partes review (IPR) petitions filed by Amgen at the Patent Trial and Appeal Board (PTAB) relating to AbbVie’s drug Humira and, in a separate matter, has been acting for the same client in a patent infringement case against Gilead relating to a hepatitis C treatment. Licensing specialist Judith Hasko, white-collar crime expert Alice Fisher and the ‘commercially mindedPeter Handrinos are other names to note.

Ropes & Gray LLP had a prolific year and further cemented its position in the high-end M&A market when it acted for Pfizer on its $14bn acquisition of Medivation, and assisted Boehringer Ingelheim in a global license and collaboration agreement with AbbVie to jointly develop and commercialize a IL-23 biologic antibody for the treatment of psoriasis and other immunological indications. Practice co-chair and FDA specialist Gregory Levine represents clients before state and federal regulators in all phases of product lifecycle and assists clients with internal and government compliance investigations and enforcement actions. Levine advised a pharmaceutical manufacturer on FDA labeling and promotional issues relating to the use of new clinical data and led an internal investigation for a pharmaceutical client into a whistleblower complaint alleging violation of company anti-kickback statute guidelines. The group also has a strong patent litigation capability, and continued its successful representation of Medac, and its subsidiary Medac Pharma, in patent infringement litigation brought by Antares Pharma. Another highlight saw the team successfully defending Nevro in two IPR proceedings filed by Boston Scientific before PTAB. Steven Wilcox and Michael Beauvais are ‘extremely knowledgeable in the life sciences space’, as are Mark Bellomy, Marc Rubenstein and David McIntosh. Named individuals are based in the firm’s Boston and Washington DC offices.

Cooley LLP is best known for its emerging companies and venture capital practice, with a client roster that includes entrepreneurs, venture capitalists and financial institutions focused on the life sciences sector. The team strengthened its resources with the arrival of Jeffrey Libson and Geoffrey Starr from Pepper Hamilton LLP, as well as Manya Deehr, formerly of Life Sciences Law Group, and highly regarded IP attorney Mika Reiner Mayer, who joined from Morrison & Foerster LLP. Recent highlights include advising Otsuka Pharmaceutical on its collaboration and licensing agreement with Akebia Therapeutics for vadadustat and acting for longstanding client Jazz Pharmaceuticals on its $1.5bn acquisition of Celator Pharmaceuticals. Palo Alto-based Barbara Kosacz is recommended for public securities offerings and collaboration agreements and Laura Berezin has particular expertise in corporate securities, M&A and corporate finance transactions. In New York, Ivor Elrifi is recommended for patent prosecution, as is Wendy Goldstein for fraud and abuse investigations. Washington DC-based Michael Tuscan is another key name.

Goodwin’s transactional practice had another prolific year advising Centerview Partners (acting as the investment bank) on a number of multibillion-dollar acquisitions, which included AbbVie’s acquisition of Pharmacyclics, Galenica Group’s buyout of Relypsa and Arbor Pharmaceuticals’ deal to buy XenoPort. It also assisted Galapagos on its $2bn global partnership with Gilead Sciences, for the development and commercialization of the JAK-1-selective inhibitor filgotinib, a potential treatment for rheumatoid arthritis. Among other impressive highlights, the team advised longstanding client Moderna Therapeutics on a $474m financing, and won an appeal for Teva Pharmaceuticals in a patent case involving generic forms of Lovenox (enoxaparin sodium). Boston-based Kingsley Taft and Mitchell Bloom are co-heads of the practice, which recruited Richard Hoffman and Scott Lassman from WilmerHale and Kleinfeld, Kaplan & Becker, LLP, respectively. The group also includes experienced Hatch-Waxman litigation specialists Daryl Wiesen and David Hashmall.

King & Spalding LLP is well known for its regulatory and government enforcement capabilities, supported by its equally strong product liability and mass tort defense litigation practice. Andrew Bayman, Peter Strotz and Donald Zimmer are representing GlaxoSmithKline, as national counsel, in litigation involving the selective serotonin reuptake inhibitors (SSRIs) anti-depressant medication, Paxil. The group has also been active in the licensing and collaboration space, such as advising Jounce Therapeutics on its collaboration with Celgene to develop and commercialize immuno-oncology treatments. In a typically prolific year on the fundraising front, the practice’s California-based team acted for numerous emerging life sciences companies, such as Apama Medical, Mission Bio and Lightstone Ventures and new Enterprise Associates. Washington DC-based Seth Lundy, Mark Brown and Christina Markus focus on the regulation of drugs and compliance issues, and transactional attorneys Jon Harris and Thomas Duley are other names to note. Regulatory and compliance specialists Sheldon Bradshaw, Kyle Sampson and Gary Messplay joined from Hunton & Williams LLP in 2016. Lisa Dwyer, Preeya Noronha Pinto and Stephen Abreu are also notable practitioners.

Morgan, Lewis & Bockius LLP’s practice covers an impressively broad swathe of large-cap M&A mandates supplemented by strong FDA, regulatory and IP litigation capabilities. The firm advised Acerta Pharma on the $4bn sale of a majority stake in its company to AstraZeneca, and assisted Teva Pharmaceutical Industries with the $40.5bn acquisition of Allergan’s global generic pharmaceuticals business. Richard de Bodo serves as lead trial counsel in patent and trade secret cases, and recently successfully litigated two high-stakes Hatch-Waxman patent litigation in the District of New Jersey for Allergan, Forest Laboratories and the Aptalis companies (Aptalis) pertaining to Aptalis’ Canasa pharmaceutical product. Xencor is another key client, which the team assisted in its collaboration and licensing agreement with Novartis for the development of cancer treatments. Randall Sunberg and Jeffry Mann jointly head the life sciences group from the Princeton and San Francisco offices, respectively. Kathleen Sanzo, Elizabeth Bierman and Michele Buenafe focus on regulatory, compliance and enforcement issues, Alan Leeds counts Merck, Lundbeck and Biovail among his clients, while Chicago-based Michael Abernathy has trial experience with Section 337 investigations in the US International Trade Commission.

DLA Piper LLP (US) is praised for its ‘deep understanding of the life sciences industry and its outstanding litigation capability’. The team can also leverage its global network of offices to advise major pharmaceutical companies, research institutions and universities on big-ticket cross-border transactions and high profile contentious matters. The group showed its dedication to the sector when it added a number of well-regarded attorneys in its corporate, regulatory and IP teams, including FDA regulatory specialist George Karavetsos, who joined from a senior in-house role at the US Food and Drug Administration’s Office of Criminal Investigations. The ‘smart and strategicLoren Brown and Raymond Williams have been acting for Novo Nordisk as national coordinating counsel and trial counsel in federal and state court litigation involving the type-2 diabetes medication, Victoza. Lisa Haile and Stuart Pollack have been representing SteadyMed Therapeutics in an IPR petition to PTAB against United Therapeutics, relating to a process to purify prostacyclin derivatives, such as treprostinil. Product liability and mass tort expert Matthew Holian has ‘a very good sense of legal issues and business issues, and has a great way of explaining issues in a user-friendly way’. Other highlights included acting for Pozen during its acquisition of Tribute Pharmaceuticals Canada to create Aralez Pharmaceuticals, and representing Biogen in its product liability lawsuit involving Tecfidera, its flagship multiple sclerosis medication. Larry Nishnick, who splits his time between San Diego and Los Angeles, is another name to note along with patent litigator Aaron Fountain, who excels in proceedings before PTAB. The group has a presence in San Diego, Washington DC, New York, Silicon Valley, Boston and San Francisco.

Antitrust specialist George Gordon and corporate partner David Schulman jointly head the global life sciences practice at Dechert LLP, which excels in the corporate and litigation space, as well as in IP counseling and litigation. Endo Pharmaceutical is a key client of the group; in 2016, Gordon led a team of antitrust litigators in Federal Trade Commission v. Endo Pharmaceuticals Inc, et al, in which he defended Endo Pharmaceuticals in the Federal Trade Commission’s challenge to an agreement by the drug manufacturer not to develop an authorized generic drug. Patent litigator Martin Black secured a victory in the District of Delaware against seven manufacturers of generic drugs for the infringement of an additional patent from its Opana ER tablets, which it has exclusively licensed from Mallinckrodt. Other notable mandates included advising Celgene on its $2.6bn collaboration with Jounce Therapeutics to co-develop and commercialize JTX-2011, a preclinical agent being developed to treat tumors, and assisting Janssen Pharmaceutica with the sale of five anesthesia and pain management injectable products to the UK healthcare unit of Indian conglomerate Piramal Enterprises. Capital markets specialist Kristopher Brown is noted for ‘the strength of his client relationships’, and patent attorney and litigator Andrea Reid’s advice is ‘thoughtful and thorough’. Tony Chan is also highly recommended. All individuals mentioned above are based in Philadelphia, New York and Boston.

Trusted Advisor - with Finnegan

IP specialist Finnegan detail how their collaborative approach makes for a unique culture which is designed to allow them to work with clients in a way which is cognizant of the challenges facing all companies today.

Foley & Lardner LLP’s life sciences group draws upon its market leading patent prosecution and ligation capabilities to advise a broad range of global pharmaceutical companies on their IP needs. Washington DC-based Stephen Maebius is representing United Therapeutics in an IPR petition case filed by SteadyMed to defend a patent which relates to a process to further purify prostacyclin derivatives, such as treprostinil. FDA regulatory specialist David Rosen and government investigations expert Judith Waltz are also names to note along with Beni Surpin and Richard Kaufman, who assisted with a number of patent licensing transactions and collaboration agreements. Andrew Hurst, who specializes in acting for life sciences companies in civil fraud investigations and litigation, joined from Reed Smith LLP.

McDermott Will & Emery LLP is best known for its corporate and IP practice. In one highlight, the team secured a jury trial victory for Amgen in a patent suit brought against Sanofi and Regeneron Pharmaceuticals regarding the new generation of cholesterol lowering drugs, and advised Seikagaku on its Supartz FX distribution agreement with Bioventus. The group is led by Boston-based Byron Kalogerou and also includes Chicago-based Kristian Werling plus William Gaede and Paul DeStefano, who are both based in Silicon Valley.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has robust capability in the transactional space with notable strengths in securities offerings and asset acquisitions. Jonathan Kravetz’s recent instructions include advising Myriad Genetics on its acquisition of Assurex Health, and acting for the underwriters in the follow-on public offerings of GW Pharmaceuticals and Acceleron Pharma. The team also assisted with the IP aspect of Johnson & Johnson’s $4.3bn acquisition of Abbott Medical Optics. Jeffrey Wiesen and William Whelan are the key figures in Boston.

Reed Smith LLP’s life sciences group, which is led by Princeton-based Diane Frenier and Melissa Geist together with Scot Hasselman in Washington DC, acts for a broad range of clients, including public and private life sciences start-ups and companies with developmental therapies. The practice’s capability spans commercial and corporate transactions, FDA regulatory expertise and market-leading product liability litigation. The team has been serving as trial counsel for GlaxoSmithKline in product liability litigation before courts in California involving Avandia, a prescription type-2 diabetes treatment. Century City-based Michael Sanders recently assisted Sonendo in its series D preferred stock financing, handled the $380m acquisition of Sequent Medical by MicroVention, and acted for Ritter Pharmaceuticals in its follow-on common stock purchase agreement with Aspire Capital Fund. Lisa Chiarini, who focuses on patent litigation and counseling, joined from Fish & Richardson P.C. in 2016, and patent litigators Joshua Davis and Nicolas Barzoukas joined the Houston office from Baker Botts L.L.P..

Skadden, Arps, Slate, Meagher & Flom LLP has an outstanding record in M&A work, backed by strong regulatory, IP and litigation practices. The group handled a number of large-cap transactions, including Gilead Sciences’ $1.2bn purchase of Nimbus Therapeutics, acting for the target in Allergan’s $1.6bn acquisition of Tobira Therapeutics, and representing Representaciones E Investigaciones Médicas during its $2.3bn acquisition by Teva Pharmaceutical Industries. New York-based Douglas Nemec defended Johnson Matthey in a lawsuit brought by Shire Pharmaceuticals alleging infringement or future infringement of patents relating to the manufacture and sale of Vyvanse. The capital markets team assisted Patheon in its $625m IPO of ordinary shares and listing on the New York stock exchange and advised Strongbridge Biopharma on its redomiciliation from Sweden to Ireland. In Washington DC, Jennifer Bragg focuses on advising pharmaceuticals companies on FDA regulatory and healthcare compliance matters; Boston-based Graham Robinson, along with New York-based Andrea Nicolas and Paul Schnell are key figures for transactions.

The life sciences group at WilmerHale is a core contributor to the work generated by the corporate, IP, litigation and regulatory practices. IP litigator Amy Wigmore achieved a victory for Bristol-Myers Squibb in a patent infringement action involving two patents held by Genetic Technologies, where the Federal Circuit ruled that claims of a patent on a method of detecting genetic variations were invalid. Boston-based patent trial lawyer William Lee is also highly recommended and, with the support of Lisa Pirozzolo, has been representing GlaxoSmithKline in a patent infringement suit against Pfizer relating to meningitis vaccines in the District of New Jersey. Recent work for the corporate team includes variously acting for Summit Therapeutics on its licensing and collaboration agreement with Sarepta Therapeutics; assisting Spark Therapeutics with a $157m follow-on offering; and advising Intercept Pharmaceuticals on its $460m underwritten public offering of convertible senior notes. The life sciences team, which is mostly based in Boston, is led by Stuart Falber and Belinda Juran, and also includes Lia Der Marderosian, New York-based Steven Singer and Robert Gunther and Washington DC-based Bruce Manheim.

Dentons handles a broad range of transactions for public and private companies, and also assists issuers, underwriters and venture capital investors with a wide range of matters. The team is representing GlaxoSmithKline in a negligence suit over warning labels on the generic version of its antidepressant Paxil, which allegedly failed to highlight increased risks in adults. San Diego-based Stephanie Seidman has extensive patent counseling experience, notably patent portfolios involving complex technologies using therapeutic proteins, small molecules, antibodies and diagnostics. The IP group is assisting Monsanto with all aspects of strategic patent portfolio management, including patent interference and opposition proceedings, and a series of IPR proceedings involving patents covering healthier soybean seed oils and plants. Venture technology specialist Jeffrey Baumel and litigator Peg Donahue Hall are the main contacts along with Dallas-based Robert Hanson, who focuses on patent counseling and prosecution.

Gibson, Dunn & Crutcher LLP had another prolific year in the transactional space - it acted for St Jude Medical during its $3.4bn acquisition of Thoratec and the client’s subsequent $30.7bn purchase by Abbott Laboratories; other work included assisting Arrowhead Pharmaceuticals with a $670m licensing and collaboration agreement with Amgen to develop RNA interference therapies for cardiovascular disease. The IP litigation team secured a major patent victory against three generic companies regarding the opioid drug Nucynta. San Francisco-based Ryan Murr, Dallas-based Tracey Davies and New York-based Daniel Thomasch are the practice co-heads. Patent litigators Wayne Barsky, Jane Love and Robert Trenchard, and FDA regulatory specialist Stephen Payne are other names to note.

Jones Day combines its transactional, tort litigation and patent litigation capabilities with a solid Washington DC-based compliance and FDA regulatory group. The business and tort litigation group is defending Celgene in proceedings concerning a federal and state False Claims Act case brought by a former employee pending in the Central District of California. Deal highlights included Irvine-based Kevin Espinola advising BioMarin Pharmaceutical on its $525m acquisition of the global rights of Kuvan and pegvaliase from Merck Serono. The IP team also had a prolific year, successfully representing Idenix in a patent infringement case against Gilead Sciences over sofobuvir, the active ingredient in Gilead’s hepatitis C drugs Sovaldi and Harvoni, and defending AbbVie in an IPR petition brought by Coherus Biosciences against a patent, directed to formulations for AbbVie’s antibody therapeutics Humira. Stephen Sozio, Maureen Bennett and Anthony Insogna are the main contacts. The life sciences group has teams in New York, San Diego, Silicon Valley and Washington DC.

Norton Rose Fulbright US LLP’s reputation rests on big-ticket litigation and an impressive record of deals and licensing partnerships. New York-based Andres Liivak advised ViiV Healthcare on its purchase of Bristol-Myers Squibb’s late-stage HIV research and development assets and, in a separate deal, handled its agreement to acquire Bristol-Myers Squibb’s HIV portfolio of pre-clinical and discovery stage research assets; he also assisted Pfizer with its strategic drug discovery collaboration with Heptares Therapeutics. The IP team, which includes Charles Walker and US head of IP Gina Shishima, is representing CeramTec and its medical device customers in a patent infringement case filed by plaintiff CeraMedic. Frederick Robinson, Steven Suzzan and Lesley Reynolds are the main contacts. The group has a presence in New York, Houston, Washington DC and Austin.

O’Melveny & Myers LLP’s strengths lie in its strong patent and product liability litigation practice and its government and internal investigations capabilities. First chair trial lawyer Lisa Pensabene regularly acts in high-stakes patent litigation for leading pharmaceutical companies, and is representing AstraZeneca in the Hatch-Waxman litigation relating to breast cancer drug Faslodex (fulvestrant). In other highlights, the team handled Sinocare’s purchase of Trividia Health from Nipro and its acquisition of PTS Diagnostics. The team expanded its regulatory offering with the hire of senior counsel Seth Ray, who joined from a senior in-house role at the FDA. Scott Elliott, Ross Galin, Richard Goetz and Portia Ku are the key contacts; they are based in New York, Los Angeles, Silicon Valley and San Francisco, respectively.

Weil, Gotshal & Manges LLP’s product liability group is highly experienced in representing clients in high-stakes litigation, as is its patent litigation team, which handles a steady flow of high-profile mandates. Notable recent achievements in the transactional space include assisting Sanofi with its $25bn business swap deal exchanging its animal health business for the consumer healthcare business of Boehringer Ingelheim, and successfully securing clearance from the Federal Trade Commission for Allergan’s sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries. Jeffrey Osterman advised Sanofi on its exclusive worldwide licensing agreement with Hanmi Pharmaceutical to develop and commercialize a portfolio of diabetes treatments. The team is led by Silicon Valley-based Edward Reines and also includes highly regarded patent litigator Elizabeth Weiswasser in New York.

The West Coast group at Wilson Sonsini Goodrich & Rosati expanded its corporate offering by hiring Lowell Segal, who joined from Ropes & Gray LLP in 2016. The life sciences practice also has notable strength in IP litigation, as well as in collaboration and licensing transactions. The team acted for Abbott’s financial adviser Evercore on its $25bn acquisition of St Jude Medical and is assisting Tolero Pharmaceuticals with its acquisition by Sumitomo Dainippon Pharma. Vern Norviel, Douglas Carsten and Kenneth Clark are the main contacts.

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

The Legal 500 United States - Events

GC Powerlist -
United States

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to
  • Bär & Karrer Advises CEVA Logistics on its IPO, the anchor investment by CMA CGM and its migration

    CEVA Logistics, one of the world's leading third-party logistics companies, successfully priced its IPO and listed its shares on the SIX Swiss Exchange, where trading commenced on 4 May 2018. With a market capitalization of CHF 1.6 billion and generating gross proceeds of CHF 821 million, this is so far considered as the largest IPO on the SIX Swiss Exchange for 2018. In addition, CMA CGM, the third largest container shipping group in the world, has committed to make a strategic cornerstone investment in CEVA Logistics by purchasing CHF 379 million of mandatory convertible securities which will convert into shares of CEVA Logistics once certain regulatory approvals have been obtained. Simultaneously with the IPO, CEVA Holdings, the former holding company of the CEVA group, migrated from the Marshall Islands to Switzerland by way of a cross-border merger with CEVA Logistic as the surviving company.
  • BAG: Employer not liable for harm caused by vaccine

    Employers who have flu vaccines administered within their company are not liable for any harm that might occur as a result of the vaccine. That was the verdict of the Bundesarbeitsgericht (BAG), Germany’s Federal Labour Court, in a recent ruling.
  • Tax Update

    Cyprus Tax Department has announced that, as of June 1 st 2018 , the following taxes, not bearing interest and charges, can ONLY be paid via JCCsmart (website ) . JCCsmart is a Cyprus portal used to contact payments to various organizations including the Government. This measure follows the successful implementation of the Pay As You Earn (PAYE) tax withheld from employees through JCCsmart.
  • Bär & Karrer Advises on the Financing of the Largest Thermoelectric Plant in Latin America

    Centrais Elétricas de Sergipe S.A. (CELSE) has successfully issued bonds for approx. USD 1 billion equivalent in local currency at a fixed, long-term rate in international capital markets. The innovative bond issue is guaranteed by the Swiss Export Risk Insurance (SERV), the export credit agency of Switzerland. The bonds are part of a financial package to finance the development, design, construction, operation and maintenance of a thermoelectric power plant by CELSE in the state of Sergipe in the northeast region of Brazil. Besides the bond issue for approx. USD 1 billion, the transaction includes a USD 200 million loan from the International Finance Corporation and a financial package of the Inter-American Development Bank in the amount of approx. USD 300 million. Once operational expected for in 2020, CELSE will sell electricity to 26 distribution companies in Brazil, becoming the largest and most efficient thermoelectric plant in Latin America and the Caribbean.
  • BAG: Threats made by employee can justify dismissal with immediate effect

    Employers do not have to accept threats made by employees. These can constitute good cause justifying extraordinary notice of dismissal with immediate effect, as demonstrated by a ruling of the Bundesarbeitsgericht (BAG), Germany’s Federal Labour Court.
  • SyCipLaw is Tier 1 Firm in IP STARS 2018 Rankings

    SyCip Salazar Hernandez & Gatmaitan (SyCipLaw) was once again ranked by Managing IP’s IP STARS 2018 as a Tier 1 firm in Patent and Trademarks/Copyright in the Philippines. In addition, SyCipLaw partners Enrique T. Manuel and Vida M. Panganiban-Alindogan are ranked as Trade mark star – Philippines . Mr. Manuel is also ranked as Patent star – Philippines .
  • Bär & Karrer Advises on Partial Self-Tender Offer

    On 21 September 2017, an extraordinary shareholders' meeting of the SIX Swiss Exchange listed N.V. authorized the board of directors to repurchase up to 33 1/3% of the company's share capital by means of a partial self-tender offer. The resolution adopted under Dutch law contained detailed information, among others regarding the period for which the authorization is granted, the manner in which the shares are repurchased and the price range within which the offer price must be set.
  • New Serbian Law on Foreigners Adopted

    In March 2018, the new Serbian Law on Foreigners was adopted, replacing the 2008 version of this law- in force until recently without any amendments. The new law will enter into force on 3 October 2018.
  • The Serbian Law on Foreign Exchange Amended

    On 20 April 2018, the amendments to the Law on Foreign Exchange (the “Law ”) were adopted and will enter into force on 28 April 2018 . Exceptionally, the application of certain provisions related to the assuming of competencies over foreign exchange control by the National Bank of Serbia is delayed until 1 January 2019.
  • Bär & Karrer Advises Vyaire Medical on its Acquisition of Acutronic Medical Systems

    Vyaire Medical, Inc., a global leader in respiratory care, acquired all shares in the Acutronic Medical Systems group, a Switzerland and Germany-based leader in the design and manufacture of neonatal ventilation equipment.